お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
989540

抗ウイルス治療薬市場規模調査:薬剤別、流通別(~2025年)、COVID-19の累積的影響

Antiviral Therapeutics Market Research Report by Drug, by Distribution - Global Forecast to 2025 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 197 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.25円
抗ウイルス治療薬市場規模調査:薬剤別、流通別(~2025年)、COVID-19の累積的影響
出版日: 2021年02月11日
発行: 360iResearch LLP
ページ情報: 英文 197 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗ウイルス治療薬の市場規模は、2020年の568億9137万米ドルから、2025年末までに813億8443万米ドルに成長すると予想されています。

市場セグメンテーションとカバレッジ

当調査は、抗ウイルス治療薬の世界市場を分類して、収益を予測し、次の各サブマーケットの動向を分析します。

  • 薬物別だと、抗ウイルス治療薬市場は、HIV抗ウイルス薬、肝炎抗ウイルス薬、ヘルペス抗ウイルス薬、およびインフルエンザ抗ウイルス薬にわたって調査されました。
  • 流通別だと、抗ウイルス治療薬市場は病院薬局、独立薬局&ドラッグストア、およびオンライン薬局全体で調査されました。
  • 地域別だと、抗ウイルス治療薬市場は南北アメリカ、アジア太平洋、欧州、中東・アフリカで調査されました。南北アメリカ地域ではアルゼンチン、ブラジル、カナダ、メキシコ、および米国で調査されました。アジア太平洋地域ではオーストラリア、中国、インド、インドネシア、日本、マレーシア、フィリピン、韓国、タイで調査されました。欧州、中東、およびアフリカ地域だと、フランス、ドイツ、イタリア、オランダ、カタール、ロシア、サウジアラビア、南アフリカ、スペイン、アラブ首長国連邦、および英国全体で調査されました。

COVID-19の累積的影響

COVID-19は、ほぼすべての業界に影響を与えた比類のない世界的な公衆衛生上の緊急事態であるため、予測期間中に業界の成長に長期的な影響を与えると予測されます。私たちの進行中の調査は、調査フレームワークを増幅して、基礎となるCOVID-19の問題と今後の潜在的な道筋を確実に含めるようにしています。調査は消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場の力のダイナミクス、および政府の重要な介入を考慮したCOVID-19に関する洞察を提供しています。更新された調査は、市場へのCOVID-19の影響を考慮して、洞察、分析、推定、および予測を提供します。

レポートは、次の指針に関する洞察を提供します。

  • 1.市場浸透:主要なプレーヤーにより提供される市場に関する包括的な情報
  • 2.市場開発:収益性の高い新興市場に関する詳細な情報と市場分析
  • 3.市場の多様化:新製品の発売、未開発の地域、最近の開発、および投資に関する詳細情報
  • 4.競争力のある評価とインテリジェンス:主要企業の市場シェア、戦略、製品、製造能力の徹底的な評価を提供します
  • 5.製品開発とイノベーション:将来のテクノロジー、R&D活動、および新製品開発に関する洞察

レポートは次のような質問に答えます。

  • 1.世界の抗ウイルス治療薬市場の市場規模と予測はどのくらいですか?
  • 2.予測期間中に世界の抗ウイルス治療薬市場を形成するCOVID-19の阻害要因と影響は何ですか?
  • 3.世界の抗ウイルス治療薬市場の予測期間中に投資する製品/セグメント/アプリケーション/分野はどれですか?
  • 4.世界の抗ウイルス治療薬市場における機会の競争戦略的ウィンドウは何ですか?
  • 5.世界の抗ウイルス治療薬市場動向技術動向と規制の枠組みは何ですか?
  • 6.世界の抗ウイルス治療薬市場に参入するのに適していると考えられるモードと戦略的動きは何ですか?

当レポートでは、抗ウイルス治療薬市場を調査し、市場概要、市場の成長要因および阻害要因の分析、薬剤別、流通別、地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイル、市場機会など、包括的な情報を提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションとカバレッジ
  • 調査対象年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画を作成する
    • 実行:調査を実施する
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • イントロダクション
  • 市場の見通し
  • 医薬品の見通し
  • 流通見通し
  • 地域展望
  • 競合他社の見通し

第4章 市場概要

  • イントロダクション
  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 世界の抗ウイルス治療薬市場:医薬品別

  • イントロダクション
  • HIV抗ウイルス薬
  • 肝炎抗ウイルス薬
  • ヘルペス抗ウイルス薬
  • インフルエンザ抗ウイルス薬

第7章 世界の抗ウイルス治療薬市場:流通別

  • イントロダクション
  • 病院薬局
  • 独立した薬局&ドラッグストア
  • オンライン薬局

第8章 南北アメリカの抗ウイルス治療薬市場

  • イントロダクション
  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の抗ウイルス治療薬市場

  • イントロダクション
  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第10章 欧州、中東・アフリカの抗ウイルス治療薬市場

  • イントロダクション
  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併と買収
    • 合意、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第12章 企業のユーザビリティプロファイル

  • Abbott Laboratories
  • AbbVie Inc.
  • Atea Pharmaceuticals
  • Aurobindo Pharma Limited
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • COCRYSTAL PHARMA, INC.
  • Daiichi Sankyo Co. Ltd.
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Services
  • Merck & Co.
  • Pfizer Inc.
  • Sanofi S.A.
  • Schering-Plough Corporation
  • Venatorx Pharmaceuticals, Inc.
  • Vienna BioCenter

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

List of Figures

  • FIGURE 1. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: RESEARCH EXECUTION
  • FIGURE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2020 VS 2025 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2025 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: MARKET DYNAMICS
  • FIGURE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 13. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2020 VS 2025 (%)
  • FIGURE 14. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2020 VS 2025 (USD MILLION)
  • FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2025
  • FIGURE 16. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV ANTIVIRAL DRUG, 2020 VS 2025 (USD MILLION)
  • FIGURE 17. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS ANTIVIRAL DRUG, 2020 VS 2025 (USD MILLION)
  • FIGURE 18. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES ANTIVIRAL DRUG, 2020 VS 2025 (USD MILLION)
  • FIGURE 19. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA ANTIVIRAL DRUG, 2020 VS 2025 (USD MILLION)
  • FIGURE 20. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2020 VS 2025 (%)
  • FIGURE 21. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2020 VS 2025 (USD MILLION)
  • FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2025
  • FIGURE 23. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2020 VS 2025 (USD MILLION)
  • FIGURE 24. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY & DRUG STORE, 2020 VS 2025 (USD MILLION)
  • FIGURE 25. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, 2020 VS 2025 (USD MILLION)
  • FIGURE 26. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 27. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 28. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 29. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 30. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 31. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 32. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 33. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 34. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 35. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 37. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 38. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 39. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 40. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 41. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 42. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 43. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 44. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 45. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 46. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 47. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 49. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 50. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 51. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 52. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 53. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 54. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 55. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 56. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 57. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 58. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 59. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 60. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: 360IRESEARCH™ FPNV POSITIONING MATRIX
  • FIGURE 61. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: 360IRESEARCH™ MARKET SHARE ANALYSIS
  • FIGURE 62. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: COMPETITOR SWOT ANALYSIS
  • FIGURE 63. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTIVIRAL THERAPEUTICS MARKET, BY TYPE

List of Tables

  • TABLE 1. CURRENCY CONVERSION RATES
  • TABLE 2. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV ANTIVIRAL DRUG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS ANTIVIRAL DRUG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES ANTIVIRAL DRUG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA ANTIVIRAL DRUG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY & DRUG STORE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: SCORES
  • TABLE 73. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: BUSINESS STRATEGY
  • TABLE 74. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: PRODUCT SATISFACTION
  • TABLE 75. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: RANKING
  • TABLE 76. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: MERGER & ACQUISITION
  • TABLE 77. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 78. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 79. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: INVESTMENT & FUNDING
  • TABLE 80. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 81. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: LICENSE & PRICING
目次
Product Code: MRR-DB2592C

Title:
Antiviral Therapeutics Market Research Report by Drug (HIV Antiviral Drug, Hepatitis Antiviral Drug, Herpes Antiviral Drug, and Influenza Antiviral Drug), by Distribution (Hospital Pharmacy, Independent Pharmacy & Drug Store, and Online Pharmacy) - Global Forecast to 2025 - Cumulative Impact of COVID-19.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

  • 1. The Global Antiviral Therapeutics Market is expected to grow from USD 56,891.37 Million in 2020 to USD 81,384.43 Million by the end of 2025.
  • 2. The Global Antiviral Therapeutics Market is expected to grow from EUR 49,883.43 Million in 2020 to EUR 71,359.41 Million by the end of 2025.
  • 3. The Global Antiviral Therapeutics Market is expected to grow from GBP 44,346.48 Million in 2020 to GBP 63,438.67 Million by the end of 2025.
  • 4. The Global Antiviral Therapeutics Market is expected to grow from JPY 6,071,750.80 Million in 2020 to JPY 8,685,780.96 Million by the end of 2025.
  • 5. The Global Antiviral Therapeutics Market is expected to grow from AUD 82,613.83 Million in 2020 to AUD 118,181.01 Million by the end of 2025.

Market Segmentation & Coverage:

This research report categorizes the Antiviral Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Drug, the Antiviral Therapeutics Market studied across HIV Antiviral Drug, Hepatitis Antiviral Drug, Herpes Antiviral Drug, and Influenza Antiviral Drug.
  • Based on Distribution, the Antiviral Therapeutics Market studied across Hospital Pharmacy, Independent Pharmacy & Drug Store, and Online Pharmacy.
  • Based on Geography, the Antiviral Therapeutics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Antiviral Therapeutics Market including Abbott Laboratories, AbbVie Inc., Atea Pharmaceuticals, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Cipla Inc., COCRYSTAL PHARMA, INC., Daiichi Sankyo Co. Ltd., Eli Lilly & Co., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline PLC, Janssen Pharmaceuticals, Inc., Johnson & Johnson Services, Merck & Co., Pfizer Inc., Sanofi S.A., Schering-Plough Corporation, Venatorx Pharmaceuticals, Inc., and Vienna BioCenter.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

360iResearch™ FPNV Positioning Matrix:

The 360iResearch™ FPNV Positioning Matrix evaluates and categorizes the vendors in the Antiviral Therapeutics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

360iResearch™ Competitive Strategic Window:

The 360iResearch™ Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch™ Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Antiviral Therapeutics Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antiviral Therapeutics Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antiviral Therapeutics Market?
  • 4. What is the competitive strategic window for opportunities in the Global Antiviral Therapeutics Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Antiviral Therapeutics Market?
  • 6. What are the modes and strategic moves considered suitable for entering the Global Antiviral Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Stakeholders

2. Research Methodology

  • 2.1. Research Process
    • 2.1.1. Define: Research Objective
    • 2.1.2. Determine: Research Design
    • 2.1.3. Prepare: Research Instrument
    • 2.1.4. Collect: Data Source
    • 2.1.5. Analyze: Data Interpretation
    • 2.1.6. Formulate: Data Verification
    • 2.1.7. Publish: Research Report
    • 2.1.8. Repeat: Report Update
  • 2.2. Research Execution
    • 2.2.1. Initiation: Research Process
    • 2.2.2. Planning: Develop Research Plan
    • 2.2.3. Execution: Conduct Research
    • 2.2.4. Verification: Finding & Analysis
    • 2.2.5. Publication: Research Report
  • 2.3. Research Outcome

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Drug Outlook
  • 3.4. Distribution Outlook
  • 3.5. Geography Outlook
  • 3.6. Competitor Outlook

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cumulative Impact of COVID-19

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of viral diseases like HIV and Hepatitis
      • 5.1.1.2. Application of antiviral therapeutics in pediatric care and respiratory diseases
      • 5.1.1.3. Increasing initiatives to curb viral diseases by public and private companies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with antiviral drug treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in molecular biology promoting drug development
      • 5.1.3.2. Improved testing and analysis of viral infections
    • 5.1.4. Challenges
      • 5.1.4.1. Moving towards the development of new drug development formula
  • 5.2. Porters Five Forces Analysis
    • 5.2.1. Threat of New Entrants
    • 5.2.2. Threat of Substitutes
    • 5.2.3. Bargaining Power of Customers
    • 5.2.4. Bargaining Power of Suppliers
    • 5.2.5. Industry Rivalry

6. Global Antiviral Therapeutics Market, By Drug

  • 6.1. Introduction
  • 6.2. HIV Antiviral Drug
  • 6.3. Hepatitis Antiviral Drug
  • 6.4. Herpes Antiviral Drug
  • 6.5. Influenza Antiviral Drug

7. Global Antiviral Therapeutics Market, By Distribution

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Independent Pharmacy & Drug Store
  • 7.4. Online Pharmacy

8. Americas Antiviral Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Antiviral Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. South Korea
  • 9.10. Thailand

10. Europe, Middle East & Africa Antiviral Therapeutics Market

  • 10.1. Introduction
  • 10.2. France
  • 10.3. Germany
  • 10.4. Italy
  • 10.5. Netherlands
  • 10.6. Qatar
  • 10.7. Russia
  • 10.8. Saudi Arabia
  • 10.9. South Africa
  • 10.10. Spain
  • 10.11. United Arab Emirates
  • 10.12. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
    • 11.1.1. Quadrants
    • 11.1.2. Business Strategy
    • 11.1.3. Product Satisfaction
  • 11.2. Market Ranking Analysis
  • 11.3. Market Share Analysis
  • 11.4. Competitor SWOT Analysis
  • 11.5. Competitive Scenario
    • 11.5.1. Merger & Acquisition
    • 11.5.2. Agreement, Collaboration, & Partnership
    • 11.5.3. New Product Launch & Enhancement
    • 11.5.4. Investment & Funding
    • 11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles

  • 12.1. Abbott Laboratories
  • 12.2. AbbVie Inc.
  • 12.3. Atea Pharmaceuticals
  • 12.4. Aurobindo Pharma Limited
  • 12.5. Bristol-Myers Squibb Company
  • 12.6. Cipla Inc.
  • 12.7. COCRYSTAL PHARMA, INC.
  • 12.8. Daiichi Sankyo Co. Ltd.
  • 12.9. Eli Lilly & Co.
  • 12.10. F. Hoffmann-La Roche AG
  • 12.11. Gilead Sciences Inc.
  • 12.12. GlaxoSmithKline PLC
  • 12.13. Janssen Pharmaceuticals, Inc.
  • 12.14. Johnson & Johnson Services
  • 12.15. Merck & Co.
  • 12.16. Pfizer Inc.
  • 12.17. Sanofi S.A.
  • 12.18. Schering-Plough Corporation
  • 12.19. Venatorx Pharmaceuticals, Inc.
  • 12.20. Vienna BioCenter

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.